ESR2 and breast cancer: Collectively, these data suggest that mitochondrial ER-β is a target for endocrine therapy agents in breast cancer cells lacking ER-α expression and mitochondrial ER-β and ER-α differentially regulate response to endocrine therapy and mitochondrial priming.